Sort   by:  
 Page size 
UnknownCOVID-19 pandemic impairs medical care of vasculitis patients in Germany: Results of a national patient survey.
Not available
S-EPMC9868561 | biostudies-literature
UnknownEvaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
Not available
S-EPMC7254609 | biostudies-literature
Unknown[Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV‑2/COVID‑19 pandemic, including recommendations for COVID‑19 vaccination].
Not available
S-EPMC8311067 | biostudies-literature
UnknownA candidate gene approach identifies an IL33 genetic variant as a novel genetic risk factor for GCA.
Not available
S-EPMC4237421 | biostudies-literature
UnknownMepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
Not available
S-EPMC9305132 | biostudies-literature
UnknownIdentification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis.
Not available
S-EPMC4053592 | biostudies-literature
UnknownGenome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status.
Not available
S-EPMC6851141 | biostudies-literature
UnknownMepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Not available
S-EPMC5548295 | biostudies-literature
UnknownAssessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise.
Not available
S-EPMC6690481 | biostudies-literature
UnknownA large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.
Not available
S-EPMC4385191 | biostudies-literature
Sort   by:  
 Page size